|

NAI Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anktiva, IL-15, Interleukin-15

Pipeline

Phase 2: 1

Top Sponsors

  • Glenn J. Hanna1

Indications

  • Metastatic Head and Neck Cancer1
  • Recurrent Head and Neck Cancer1
  • Recurrent Head and Neck Squamous Cell Carcinoma1
  • Metastatic Head and Neck Squamous Cell Carcinoma1
  • Head and Neck Cancer1

Boston, Massachusetts1 trial

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Brigham and Women's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.